Clinical trials: Ectopic ACTH Syndrome
Cushing Syndrome, Neoplasms
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
The primary objective is to determine the effect of relacorilant on the pharmacokinetics (PK) of the sensitive P-glycoprotein (P-gp) substrate dabigatran etexilate.
- Trial name
- NCT05347979
- Testing
- Dabigatran Etexilate, Relacorilant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Endocrine Disease, Diabetes
Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults
Background: Metabolic syndrome is a name given to a group of factors that tend to occur together. These risk factors include central obesity (extra weight around the middle of the body) and high blood pressure and blood sugar…
- Trial name
- NCT01419535
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing Syndrome, Endocrine Disease
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome is an endocrine disorder causing an over production of the hormone cortisol. Cortisol is produced in the adrenal gland as a response to the production of corticotropin (ACTH) in the pituitary gland.
- Trial name
- NCT00001849
- Testing
- Pentetreotide, 18F-DOPA, CT scan
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Anxiety, Stress
An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits
The Smart Supplement has 20 vitamins and minerals that have strong track records of demonstrating positive health effects, both physiologically and cognitively.
- Conditions
- Anxiety, Stress, Memory Deficits, Cortisol Overproduction
- Trial name
- NCT05523115
- Testing
- Heights Smart Supplement
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Heights
Cushing Syndrome
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per…
- Trial name
- NCT04543253
- Testing
- MUSE biofeedback
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Mayo Clinic
Endocrine Disorders, Adiposity
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary…
- Conditions
- Endocrine Disorders, Adiposity, Pituitary Adenoma, Cushing Syndrome
- Trial name
- NCT06326853
- Volunteers
- 200 people
- Sponsor
- IRCCS San Raffaele
Iatrogenic Cushing's Disease
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition
Currently, 2-3% of the population of the United Kingdom and United States of America receive glucocorticoid therapy. Significant adverse effects are not confined to chronic use; recurrent short-course administration is associated…
- Trial name
- TICSI (NCT03111810)
- Testing
- AZD4017 and prednisolone
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Adrenal Adenoma, Cushing Syndrome
A Prospective Cohort Study for Patients With Adrenal Diseases
The purpose of this study is to investigate the pathologic features, complications, and prognostic factors of functioning adrenal adenoma and suggest follow-up algorithms for adrenal incidentaloma.
- Conditions
- Adrenal Adenoma, Cushing Syndrome, Pheochromocytoma, Adrenal Incidentaloma
- Trial name
- NCT03474237
- Testing
- Hormone study and Imaging study
- Where
- South Korea
- Volunteers
- 1,500 people
- Sponsor
- Seoul National University Hospital
Subclinical Hypercortisolism, Cushing Syndrome
Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
Background: Adrenal tumors are a common kind of tumor. Some of these secrete extra cortisol into the body, which can lead to diabetes, obesity, and other diseases.
- Conditions
- Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
- Trial name
- NCT02001051
- Testing
- Adrenalectomy, Observation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Adrenal Tumor, Adrenal Disease
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
The goal of this multicenter, observational, analytic, randomized clinical trial is to analyze the laparoscopic and robot-assisted method in the surgical treatment of patients with adrenal diseases.
- Conditions
- Adrenal Tumor, Adrenal Disease, Adrenal Mass, Adrenalectomy; Status
- Trial name
- NCT06050057
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Olomouc
Cushing's Syndrome
Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome
OBJECTIVES: I. Evaluate whether chronic hypercortisolemia is specifically toxic to hippocampal cells and causes structural reduction of hippocampal volume in patients with Cushing's syndrome. II.
- Trial name
- NCT00004326
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Center for Research Resources (NCRR)
Cushing Syndrome, Hypercortisolism
Liquorice and Salivary Cortisol
Salivary cortisol is used as a diagnostic analysis in the investigation of suspected Cushings' syndrome. This study evaluates if liqourice intake increases salivary cortisol in healthy individuals.
- Trial name
- NCT04045015
- Testing
- Liqourice
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Umeå University
Cushing's Disease
Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease
Cushing's disease is a state of chronic endogenous glucocorticoid excess. Cushing's disease is responsible for increased morbidity and mortality.
- Trial name
- MEMOCUSH (NCT02603653)
- Testing
- Virtual radial task in 3D
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Cushing's Syndrome, Pituitary Adenoma
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands.
- Conditions
- Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease
- Trial name
- NCT00001452
- Testing
- oCRH
- Where
- United States
- Volunteers
- 1,387 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing Syndrome, Acromegaly
Muscle in Acromegaly and Cushing's Syndrome
Cushing's syndrome (CS) and acromegaly determine myopathy and muscle weakness which persist long-term after control of hormone excess.
- Trial name
- MAC (NCT03673761)
- Testing
- MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Cushing Syndrome, Metabolic Syndrome
Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism
The main hypothesis of the HEPACORT study is that upon diagnosis of endogenous Cushing's syndrome, significant liver fibrosis may be present, particularly in the most severe forms of Cushing's syndrome.
- Trial name
- HEPACORT (NCT05911620)
- Testing
- Magnetic resonance elastography (MRE)
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Central Hospital, Nancy, France
Cushing's Disease, Hypercortisolism
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress.
- Conditions
- Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
- Trial name
- OPTIMAL (NCT06701838)
- Testing
- 11C-Methionine PET/CT
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Adrenal Incidentalomas, Cushing Syndrome
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome
- Trial name
- NCT06801249
- Testing
- Metarapone, Standardized antihypertensive therapy
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Adrenal Tumour With Mild Hypercortisolism
Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome
Incidental findings of adrenal tumours,"incidentalomas", occur in 1-5 % in the general population and 10-25 % of these patients will exhibit biochemical mild hypercortisolism.
- Trial name
- AUSC (NCT01246739)
- Testing
- Adrenalectomy
- Where
- 4 sites in Denmark, Norway and 1 more
- Volunteers
- 34 people
- Sponsor
- Region Skane
Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
- Trial name
- NCT01374906
- Testing
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Where
- 82 sites in United States, Argentina and 18 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals